Startups

Neuvasq Biotechnologies

Gosselies, Belgium

Neuvasq Biotechnologies is a Belgian biotechnology company founded in February 2021 as a spin-off of Université libre de Bruxelles and scientific founder Professor Benoit Vanhollebeke. It engineers Gpr124- and Reck-targeting Wnt surrogate antibodies intended to restore blood-retina and blood-brain barrier integrity. Its lead investigational molecule NVQ401 targets vascular retinopathies, including diabetic macular edema and wet age-related macular degeneration. A second preclinical programme explores neurological diseases associated with impaired neurovascular barriers. Current published leadership lists Denis Bedoret as Executive Director and Ralph Laufer as Chief Scientific Officer. The company reports preclinical research and potential indications; no marketing approval or proven clinical efficacy is asserted. Its June 22, 2021 announcement disclosed a EUR 20 million Series A led by Newton Biocapital I, comprising EUR 10 million public and EUR 10 million private investment, with the named institutions and unnamed business angels separately qualified. Non-dilutive Walloon Region support is disclosed without public amount, date or disbursement terms. The Belgian government CBE registry confirms exact legal entity NEUVASQ BIOTECHNOLOGIES, enterprise BE0762.966.663, active since February 5, 2021, with current public limited company form effective June 18, 2021. The registry also lists legal directors/representatives not all present in the marketing directory. The registry names Christine Franssen as permanent representative of Sparaxis SA (BE0452.116.307), while the current issuer biography names Christina Franssen and describes a Wallonie Entreprendre investment role. Sparaxis is not Wallonie Entreprendre. The Christine/Christina identity bridge and different representative/employer affiliations remain unverified; no legal alias or purchasing vehicle is inferred from the marketing subtitle.

Founded 2021